Day: April 3, 2020

OMAHA, Neb., April 03, 2020 (GLOBE NEWSWIRE) — FitLife Brands, Inc. (“FitLife” or the “Company”) (OTC Pink: FTLF), an international provider of innovative and proprietary nutritional supplements for health-conscious consumers marketed under the brand names NDS Nutrition™, PMD®, SirenLabs®, CoreActive®, Metis Nutrition™, iSatori™, Energize, and BioGenetic Laboratories, is providing some preliminary performance indicators for the first quarter of 2020, along with a general operational update. The intent of this communication is to provide transparency to the shareholders of the Company given the challenges and uncertainty resulting from the COVID-19 outbreak.Preliminary results for the quarter ended March 31, 2020:Total revenue is anticipated to be in the range of $5.9-6.1 million, compared to $5.9 million during the first quarter...

LEXINGTON, Mass., April 03, 2020 (GLOBE NEWSWIRE) — Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced the appointment of Anne Prener, M.D., Ph.D., to its Board of Directors. Dr. Prener has more than 25 years of leadership experience within life sciences companies, and recently served as Chief Executive Officer (CEO) of Freeline Ltd.“We are thrilled to welcome Anne to our Board. She brings extensive experience in clinical development and commercialization in multiple therapeutic areas, which will be instrumental to Kaleido as we continue to advance our pipeline of Microbiome Metabolic Therapies (MMT™),” said Michael Bonney, Executive Chair of Kaleido’s Board of Directors.  Dr....

NEW YORK, April 03, 2020 (GLOBE NEWSWIRE) — via NetworkNewsAudio – iClick Interactive Asia Group (NASDAQ:ICLK)

CAMBRIDGE, Mass., April 03, 2020 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today provided an update on the RESTORE-1 clinical trial of VY-AADC (NBIb-1817) for Parkinson’s disease. Voyager and its collaborator Neurocrine Biosciences have temporarily paused screening of new patients in the RESTORE-1 trial to allow clinical trial sites to assess the impact of the COVID-19 pandemic on both the implementation of previously disclosed protocol amendments and on the safety of study participants. The companies plan to resume patient screening and enrollment as soon as the assessment is completed and Neurocrine, as the study sponsor, and Voyager, in consultation with clinical sites, determine that screening...

Hørsholm, Denmark, April 3rd, 2020 – Oncology Venture A/S (”Oncology Venture”) today announces that it has called upon the first tranche of SEK 10 million in line with the terms from the financing agreement communicated on March 31st, 2020. The transaction is carried out through a private placement of convertible notes. It is the first tranche out of a flexible financing agreement allowing Oncology Venture to request up to a total of SEK 100 million.This financing serves as a foundation to provide financial resources for the company’s continuing execution of its new, focused strategy, and it enables Oncology Venture to make further progress in developing its pipeline of three high-priority programs: Dovitinib, IXEMPRA®, and 2X-121.Highlights about the transaction:100 notes with a principal amount of SEK 100,000 per Note corresponding...

Novartis hat zugesagt, weltweit bis zu 130 Millionen Dosen des Malariamittels Hydroxychloroquin zu spenden, um den Kampf gegen die COVID-19-Pandemie zu unterstützen.Sandoz, die Novartis Generika- und Biosimilars Division, beginnt heute mit der Auslieferung der ersten Dosen Hydroxychloroquin an die Schweizer Behörden, die die Verteilung an die Spitäler organisierenDie Schweiz ist somit das erste europäische Land, und weltweit nach den USA das zweite, in welchem die Spende erfolgt ist.Rotkreuz, 3. April 2020 — Novartis stellt per heute eine namhafte Menge Hydroxychloroquin für die Behandlung von hospitalisierten COVID-19-Patienten in der Schweiz kostenfrei zur Verfügung. Dies mit dem Ziel, Patienten Zugang zu einer möglichen Therapie zu verschaffen und gleichzeitig die klinische Forschung im Kampf gegen COVID-19 voranzutreiben. Die Schweiz...

Novartis a promis un don mondial allant jusqu’à 130 millions de doses d’hydroxychloroquine, un antipaludique, afin d’apporter son soutien à la lutte contre la pandémie de COVID-19.Sandoz, la division de Novartis spécialisée dans les génériques et les biosimilaires, commence aujourd’hui à faire parvenir les premières doses d’hydroxychloroquine aux autorités suisses qui organisent la distribution aux hôpitaux.La Suisse est ainsi le premier pays européen, et le deuxième au monde après les Etats-Unis, à recevoir un don de ce médicament.Rotkreuz, le 3 avril 2020 — Aujourd’hui, Novartis met gratuitement à disposition des hôpitaux une quantité importante d’hydroxychloroquine afin de traiter les patients atteints du COVID-19 en Suisse. Ceci va permettre aux patients d’avoir accès à un traitement potentiellement efficace tout en faisant avancer...

Per verbal guidance, FDA to consider one additional pivotal trialFDA-generated minutes expected on or before May 1, 2020Sato Pharmaceutical to begin start-up of Phase 1 trial in JapanMORRISVILLE, N.C., April 03, 2020 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that the Company has conducted its Type C meeting with the U.S. Food and Drug Administration (“FDA”) regarding SB206 for the treatment of molluscum. The purpose of the meeting was to seek FDA feedback on the proposal to conduct one additional, well-controlled confirmatory study of SB206 to support a future New Drug Application (“NDA”).Based on guidance received during the meeting, the Company understands the FDA will consider one additional pivotal trial (“B-SIMPLE4”), if successful, to be supported by the previously completed B-SIMPLE2...

SHANGHAI, China and ROCKVILLE, MD., April 03, 2020 (GLOBE NEWSWIRE) — I-Mab (Nasdaq: IMAB) ( the “Company”), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug application (IND) to initiate clinical study for TJM2 to treat cytokine release syndrome (CRS) associated with severe illness caused by the coronavirus disease 2019 (COVID-19). The Company has also obtained central institutional review board (IRB) approval from the Western Institutional Review Board on the same day. TJM2, also known as TJ003234, is an I-Mab-discovered neutralizing antibody against human...

TORONTO, April 03, 2020 (GLOBE NEWSWIRE) — Osisko Mining Inc. (OSK:TSX, “Osisko” or the “Corporation”) is pleased to announce that it has filed a technical report in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects to update the mineral resource estimate on its 100% owned Windfall gold deposit. The technical report entitled “An updated mineral resource estimate for the Windfall Lake Project, Located in the Abitibi Greenstone Belt, Urban Township, Eeyou Istchee James Bay, Québec, Canada” and dated April 3, 2020 (effective date of January 3, 2020) has been prepared for Osisko by Micon International Limited and BBA Inc. The technical report is available on SEDAR (www.sedar.com) under Osisko’s issuer profile.About Osisko Mining Inc.Osisko is a mineral...